Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2014-01925 | Registry Identifier | NCI Clinical Trial Registration Program |
Not provided
Not provided
Not provided
Investigator's decision.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating younger patients with hematologic malignancies that have returned after or did not respond to treatment with a prior transplant. Giving chemotherapy and natural killer cells before a donor progenitor cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (progenitor cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's cells. When the healthy progenitor cells from a related donor are infused into the patient they make red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Removing specific T cells from the donor cells before the transplant may prevent this.
PRIMARY OBJECTIVE:
SECONDARY OBJECTIVES:
Blood progenitor cells will be collected from adult donors to be used for transplantation. Donor cells will be processed and filtered in a laboratory at St. Jude using a machine called the CliniMACS™ device, and later infused (transplanted) into the participant through his/her veins.
Participants undergo a conditioning regimen beginning Day 21 prior to progenitor cell transplantation that includes chemotherapy medications and natural killer cells in preparation for transplantation. They will then receive T-cell depleted HPC transplant followed by CD45RA-depleted HPC transplant the following day.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants | Experimental | Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cyclophosphamide | Drug | Given intravenously (IV) |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Engrafted by Day 42 Post-transplant | To estimate engraftment by day +42 post-transplant in patients who receive CD45RA-depleted haploidentical donor progenitor cell transplantation following reduced intensity conditioning regimen that includes haploidentical NK cells. Engraftment is defined as the first of 3 consecutive tests performed on different days of an ANC ≥ 500/mm^3 with evidence of donor cell engraftment. | Day 42 post transplantation |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Malignant Relapse | The estimate of cumulative incidence of relapse will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The number of participants with incidence of malignant relapse is given. Relapse was evaluated using standard WHO criteria for each disease. | one year post transplantation |
Not provided
Inclusion Criteria:
Age less than or equal to 21 years.
One of the following hematologic malignancies that has relapsed or remains refractory after prior allogeneic hematopoietic cell transplant (HCT):
Has a suitable single haplotype matched (≥ 3 of 6) family member donor.
Does not have any other active malignancy other than the one for which this transplant is indicated.
If prior central nervous system (CNS) leukemia, it must be treated and in CNS complete remission (CR)
Does not have current uncontrolled bacterial, fungal, or viral infection.
Patient must fulfill pre-transplant evaluation:
Left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%.
Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2.
Forced vital capacity (FVC) ≥ 40% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing.
Karnofsky or Lansky (age-dependent) performance score ≥ 50 (See Appendix A).
Bilirubin ≤ 3 times the upper limit of normal for age.
Alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal for age.
Not pregnant. If female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment.
Not breast feeding
DONOR: At least single haplotype matched (≥ 3 of 6) family member
DONOR: At least 18 years of age.
DONOR: HIV negative.
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).
DONOR: Not breast feeding.
DONOR: Regarding donation eligibility, is identified as either:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brandon Triplett, MD | St. Jude Children's Research Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | United States |
Not provided
| Label | URL |
|---|---|
| St. Jude Children's Research Hospital | View source |
| Clinical Trials Open at St. Jude | View source |
Not provided
Six enrolled participants were blood donors and did not undergo transplantation.
Twelve participants meeting eligibility criteria were enrolled at St. Jude Children's Research Hospital between November 2014 and February 2015.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Participants | Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level. Cyclophosphamide: Given intravenously (IV) Fludarabine: Given IV G-CSF: Given IV or subcutaneously (SQ) Interleukin-2: Given SQ Melphalan: Given IV Thiotepa: Given IV Rituximab: Given IV Natural killer cell therapy: Given IV T-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0. CD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fludarabine | Drug | Given IV |
|
|
| G-CSF | Biological | Given IV or subcutaneously (SQ) |
|
|
| Interleukin-2 | Biological | Given SQ |
|
|
| Melphalan | Drug | Given IV |
|
|
| Thiotepa | Drug | Given IV |
|
|
| Rituximab | Drug | Given IV |
|
|
| Natural killer cell therapy | Biological | Given IV |
|
|
| T-cell depleted HPC transplant | Biological | T-cell depleted hematopoietic stem cells will be infused on day 0. |
|
|
| CD45RA-depleted HPC transplant | Biological | CD45RA depleted stem cells will be infused on day 1. |
|
| Event-free Survival (EFS) |
The Kaplan-Meier estimate of event-free survival (EFS) along with their standard errors will be calculated using the SAS macro (bmacro251-Excel2007\kme) available in the Department of Biostatistics at St. Jude, where EFS = min (date of last follow-up, date of relapse, date of graft failure, date of death due to any cause) - date of transplant, and all participants surviving at the time of analysis without events will be censored. The number of participants who did not experience any of these events through one year post-transplant is given. |
| one year post transplantation |
| Overall Survival (OS) | The Kaplan-Meier estimate of OS along with their standard errors will be calculated using the SAS macro (bmacro251-Excel2007\kme) available in the Department of Biostatistics at St. Jude, where OS = min (date of last follow-up, date of death) - date of transplant and all participants surviving at the time of analysis without events will be censored. The number of participants surviving to one-year post-transplantation is given. | one year post transplantation |
| Incidence and Severity of Acute GvHD | The cumulative incidence of acute GvHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The severity of acute GvHD. The number of participants with incidence by grade is given. Participants are graded on a scale from 1 to 4, with 1 being mild and 4 being severe. | 100 days post transplantation |
| Incidence and Severity of Chronic GvHD | The cumulative incidence of chronic GvHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The severity of chronic GvHD will be described. Chronic GvHD was evaluated using NIH Consensus Global Severity Scoring." The number of participants with incidence by severity is given. | one year post transplantation |
| Rate of Transplant-related Mortality (TRM) | The cumulative incidence of transplant related mortality will be estimated using Kalbfleisch-Prentice method. Deaths before day 100 because of other reasons are the competing risk events. | 100 days post transplantation |
| One Year Post-transplant |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Participants | Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level. Cyclophosphamide: Given intravenously (IV) Fludarabine: Given IV G-CSF: Given IV or subcutaneously (SQ) Interleukin-2: Given SQ Melphalan: Given IV Thiotepa: Given IV Rituximab: Given IV Natural killer cell therapy: Given IV T-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0. CD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Age, Customized | Median | Full Range | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| |||||||||||||||||||||||
| Primary Diagnosis | AML = acute myeloid leukemia; MLL = myeloid-lymphoid leukemia; MDS = myelodysplastic syndrome | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants Engrafted by Day 42 Post-transplant | To estimate engraftment by day +42 post-transplant in patients who receive CD45RA-depleted haploidentical donor progenitor cell transplantation following reduced intensity conditioning regimen that includes haploidentical NK cells. Engraftment is defined as the first of 3 consecutive tests performed on different days of an ANC ≥ 500/mm^3 with evidence of donor cell engraftment. | Posted | Number | percentage of participants | Day 42 post transplantation |
|
|
| |||||||||||||||||||||||||||
| Secondary | Incidence of Malignant Relapse | The estimate of cumulative incidence of relapse will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The number of participants with incidence of malignant relapse is given. Relapse was evaluated using standard WHO criteria for each disease. | Posted | Number | participants | one year post transplantation |
|
| ||||||||||||||||||||||||||||
| Secondary | Event-free Survival (EFS) | The Kaplan-Meier estimate of event-free survival (EFS) along with their standard errors will be calculated using the SAS macro (bmacro251-Excel2007\kme) available in the Department of Biostatistics at St. Jude, where EFS = min (date of last follow-up, date of relapse, date of graft failure, date of death due to any cause) - date of transplant, and all participants surviving at the time of analysis without events will be censored. The number of participants who did not experience any of these events through one year post-transplant is given. | Posted | Number | participants | one year post transplantation |
|
| ||||||||||||||||||||||||||||
| Secondary | Overall Survival (OS) | The Kaplan-Meier estimate of OS along with their standard errors will be calculated using the SAS macro (bmacro251-Excel2007\kme) available in the Department of Biostatistics at St. Jude, where OS = min (date of last follow-up, date of death) - date of transplant and all participants surviving at the time of analysis without events will be censored. The number of participants surviving to one-year post-transplantation is given. | Posted | Number | participants | one year post transplantation |
|
| ||||||||||||||||||||||||||||
| Secondary | Incidence and Severity of Acute GvHD | The cumulative incidence of acute GvHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The severity of acute GvHD. The number of participants with incidence by grade is given. Participants are graded on a scale from 1 to 4, with 1 being mild and 4 being severe. | Two of six participants did not experience any acute GvHD. | Posted | Number | participants | 100 days post transplantation |
|
| |||||||||||||||||||||||||||
| Secondary | Incidence and Severity of Chronic GvHD | The cumulative incidence of chronic GvHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The severity of chronic GvHD will be described. Chronic GvHD was evaluated using NIH Consensus Global Severity Scoring." The number of participants with incidence by severity is given. | Posted | Number | participants | one year post transplantation |
|
| ||||||||||||||||||||||||||||
| Secondary | Rate of Transplant-related Mortality (TRM) | The cumulative incidence of transplant related mortality will be estimated using Kalbfleisch-Prentice method. Deaths before day 100 because of other reasons are the competing risk events. | All six participants who received the protocol-defined treatment were evaluable for this analysis. One participant died of a non-transplant related cause (leukemia) prior to day 100. Although this participant did not complete the study to Day 100 post-transplantation, they were still evaluable for TRM. | Posted | Number | participants | 100 days post transplantation |
| ||||||||||||||||||||||||||||
| Post-Hoc | Mean of Days to Absolute Neutrophil Count (ANC) Engraftment | ANC engraftment is defined as the first of 3 consecutive tests performed on different days of an ANC ≥ 500/mm^3 with evidence of donor cell engraftment. | Posted | Mean | Standard Deviation | days | Day 42 post transplantation |
|
| |||||||||||||||||||||||||||
| Post-Hoc | Median Days to Absolute Neutrophil Count (ANC) Engraftment | ANC engraftment is defined as the first of 3 consecutive tests performed on different days of an ANC ≥ 500/mm^3 with evidence of donor cell engraftment. | Posted | Median | Full Range | days | Day 42 post transplantation |
|
|
Adverse events were collected from study enrollment through off-study date (up to 16 months).
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Participants | Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level. Cyclophosphamide: Given intravenously (IV) Fludarabine: Given IV G-CSF: Given IV or subcutaneously (SQ) Interleukin-2: Given SQ Melphalan: Given IV Thiotepa: Given IV Rituximab: Given IV Natural killer cell therapy: Given IV T-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0. CD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1. | 5 | 6 | 6 | 6 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hemorrhage, pulmonary | Blood and lymphatic system disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Hepatic failure (disorder) | Hepatobiliary disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, candida glabrata, GI tract | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, culture negative, sepsis | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, enterococcus faecalis, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, escherichia coli, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, klebsiella oxytoca, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, pseudomonas aeruginosa, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, staphylococcus epidermidis, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, toxoplasmosis, cerebrospinal fluid | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Septic shock | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Seizure | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Cryptogenic organizing pneumonia | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Failure, pulmonary | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Respiratory failure (disorder) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Failure, renal | Renal and urinary disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hypertension | Cardiac disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Hypotension | Cardiac disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Left ventricular systolic dysfunction | Cardiac disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Mucositis | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Pneumatosis | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Epistaxis | Blood and lymphatic system disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Hemorrhage, gastrointestinal | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Abscess, mouth | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Febrile neutropenia | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, adenovirus, respiratory tract | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, adenovirus, stool | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, BK virus, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, BK virus, urine | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, candida albicans, oral mucosa | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, candida albicans, tracheostomy site | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, candida guilliermondii, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, candida lusitaniae, small intestine | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, clostridium difficile, stool | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, coagulase negative staphylococcus, pleural fluid | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, disseminated fungus, organism unknown | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, enterobacter cloacae, trachael aspirate | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, human herpes virus 6, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, rotavirus, stool | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, staphylococcus epidermidis, blood | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infection, upper respiratory | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Sinusitis | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
| |
| Hallucinations (finding) | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Involuntary movement (finding) | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Seizure | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Bronchiolitis obliterans organizing pneumonia (disorder) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Infiltrates, pulmonary | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Acute renal failure | Renal and urinary disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Failure, renal | Renal and urinary disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Acute infusion reaction, boost | General disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Acute infusion reaction, granulocyte | General disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Acute infusion reaciton, NK cells | General disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Acute infusion reaction, stem cells | General disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Cytokine release syndrome, ATG | General disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Engraftment syndrome | General disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Systemic inflammatory response syndrome (disorder) | General disorders | CTCAE (3.0) | Non-systematic Assessment |
| |
| Tumor lysis syndrome | General disorders | CTCAE (3.0) | Non-systematic Assessment |
|
The trial was terminated early due to investigator's decision.
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Brandon M. Triplett, MD | St. Jude Children's Research Hospital | 901-595-2766 | brandon.triplett@stjude.org |
| ID | Term |
|---|---|
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D015470 | Leukemia, Myeloid, Acute |
| D023981 | Sarcoma, Myeloid |
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| D054429 | Leukemia, Myelomonocytic, Juvenile |
| D009190 | Myelodysplastic Syndromes |
| D008228 | Lymphoma, Non-Hodgkin |
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D007951 | Leukemia, Myeloid |
| D012509 | Sarcoma |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009196 | Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D054437 | Myelodysplastic-Myeloproliferative Diseases |
| D008223 | Lymphoma |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| ID | Term |
|---|---|
| D003520 | Cyclophosphamide |
| C024352 | fludarabine |
| C042382 | fludarabine phosphate |
| D016179 | Granulocyte Colony-Stimulating Factor |
| D000069585 | Filgrastim |
| D007376 | Interleukin-2 |
| C082598 | aldesleukin |
| D008558 | Melphalan |
| D013852 | Thiotepa |
| D000069283 | Rituximab |
| ID | Term |
|---|---|
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D003115 | Colony-Stimulating Factors |
| D006023 | Glycoproteins |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D016298 | Hematopoietic Cell Growth Factors |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
| D007378 | Interleukins |
| D008222 | Lymphokines |
| D010649 | Phenylalanine |
| D024322 | Amino Acids, Aromatic |
| D000598 | Amino Acids, Cyclic |
| D000596 | Amino Acids |
| D013721 | Triethylenephosphoramide |
| D001388 | Aziridines |
| D001389 | Azirines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D058846 | Antibodies, Monoclonal, Murine-Derived |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided
| AML, not otherwise specified |
|
| AML, without maturation |
|
|
| Counts |
|---|
| Participants |
|
|
|
|
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
|